Pandion Therapeutics sought $58 million Series A funding to advance drug programs for autoimmune and inflammatory diseases Read more
Relmada Therapeutics obtained global rights to market dextromethadone for treating CNS diseases Read more
Eiger Biopharmaceuticals disappointed over negative results of Phase 2 LIBERTY study in PAH Read more
Marina Biotech enters into agreement with Autotelic Bio for developing Marina’s IT-103 Clinical program Read more
OBI Pharma confirms FDA’s clearance of IND for Phase 1 Study of Monoclonal Antibody Cancer Immunotherapy Read more